JP7073270B2 - 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 - Google Patents

前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 Download PDF

Info

Publication number
JP7073270B2
JP7073270B2 JP2018549808A JP2018549808A JP7073270B2 JP 7073270 B2 JP7073270 B2 JP 7073270B2 JP 2018549808 A JP2018549808 A JP 2018549808A JP 2018549808 A JP2018549808 A JP 2018549808A JP 7073270 B2 JP7073270 B2 JP 7073270B2
Authority
JP
Japan
Prior art keywords
group
compound
compound according
tumor
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018549808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519467A5 (https=
JP2019519467A (ja
Inventor
レイ サンギータ
ジー ポンパー マーティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2019519467A publication Critical patent/JP2019519467A/ja
Publication of JP2019519467A5 publication Critical patent/JP2019519467A5/ja
Priority to JP2022077992A priority Critical patent/JP2022116028A/ja
Application granted granted Critical
Publication of JP7073270B2 publication Critical patent/JP7073270B2/ja
Priority to JP2024002743A priority patent/JP2024050608A/ja
Priority to JP2025172559A priority patent/JP2026021351A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2018549808A 2016-03-22 2017-03-22 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 Active JP7073270B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022077992A JP2022116028A (ja) 2016-03-22 2022-05-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2024002743A JP2024050608A (ja) 2016-03-22 2024-01-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2025172559A JP2026021351A (ja) 2016-03-22 2025-10-14 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311697P 2016-03-22 2016-03-22
US62/311,697 2016-03-22
PCT/US2017/023508 WO2017165473A1 (en) 2016-03-22 2017-03-22 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022077992A Division JP2022116028A (ja) 2016-03-22 2022-05-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤

Publications (3)

Publication Number Publication Date
JP2019519467A JP2019519467A (ja) 2019-07-11
JP2019519467A5 JP2019519467A5 (https=) 2020-04-30
JP7073270B2 true JP7073270B2 (ja) 2022-05-23

Family

ID=59899817

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018549808A Active JP7073270B2 (ja) 2016-03-22 2017-03-22 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2022077992A Pending JP2022116028A (ja) 2016-03-22 2022-05-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2024002743A Pending JP2024050608A (ja) 2016-03-22 2024-01-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2025172559A Pending JP2026021351A (ja) 2016-03-22 2025-10-14 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022077992A Pending JP2022116028A (ja) 2016-03-22 2022-05-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2024002743A Pending JP2024050608A (ja) 2016-03-22 2024-01-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2025172559A Pending JP2026021351A (ja) 2016-03-22 2025-10-14 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤

Country Status (27)

Country Link
US (3) US11458213B2 (https=)
EP (3) EP4385981A1 (https=)
JP (4) JP7073270B2 (https=)
KR (4) KR20250057132A (https=)
CN (3) CN109311827B (https=)
AU (1) AU2017238181B2 (https=)
BR (1) BR112018069507A2 (https=)
CA (1) CA3018709A1 (https=)
CL (1) CL2018002683A1 (https=)
CY (1) CY1124487T1 (https=)
DK (2) DK3925952T3 (https=)
ES (2) ES2877572T3 (https=)
FI (1) FI3925952T3 (https=)
HR (2) HRP20211386T1 (https=)
HU (2) HUE065327T2 (https=)
LT (2) LT3433238T (https=)
MX (1) MX384823B (https=)
PH (1) PH12018502048A1 (https=)
PL (2) PL3925952T3 (https=)
PT (2) PT3925952T (https=)
RS (2) RS65188B1 (https=)
RU (2) RU2021115958A (https=)
SA (1) SA518400103B1 (https=)
SI (2) SI3925952T1 (https=)
TR (1) TR201813644T1 (https=)
WO (1) WO2017165473A1 (https=)
ZA (1) ZA201806389B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020522506A (ja) * 2017-05-30 2020-07-30 ザ・ジョンズ・ホプキンス・ユニバーシティ 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017311510B2 (en) 2016-08-10 2021-11-18 Cancer Targeted Technology Llc Chelated PSMA inhibitors
MX2019005742A (es) * 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
BR112020011727A2 (pt) 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
EP3494999A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Psma ligands for imaging and endoradiotherapy
EP3494998A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Glycosylated psma inhibitors for imaging and endoradiotherapy
US20200297877A1 (en) * 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
EP3749663A1 (en) * 2018-02-06 2020-12-16 Universität Heidelberg Fap inhibitor
US11813340B2 (en) * 2018-02-06 2023-11-14 The Johns Hopkins University PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
HRP20230604T1 (hr) 2018-03-30 2023-09-29 Futurechem Co., Ltd. Radiofarmaceutik usmjeren na psma, namijenjen dijagnosticiranju i liječenju raka prostate
WO2019240884A2 (en) 2018-04-27 2019-12-19 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
EP3856261A1 (en) * 2018-09-28 2021-08-04 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
WO2020139012A1 (ko) * 2018-12-27 2020-07-02 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
PH12021553284A1 (en) * 2019-07-02 2022-08-01 Advanced Accelerator Applications Italy Srl Prostate specific membrane antigen (psma) ligands and uses thereof
CN114096526A (zh) * 2019-07-02 2022-02-25 诺华股份有限公司 前列腺特异性膜抗原（psma）配体及其用途
RU2730507C1 (ru) * 2019-08-27 2020-08-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе
JP2023522983A (ja) * 2020-04-24 2023-06-01 ラジオメディックス インコーポレイテッド 前立腺がんの診断および処置のための組成物、キットおよび方法
IL297323A (en) 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4244216A1 (en) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
WO2022108992A1 (en) * 2020-11-17 2022-05-27 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
EP4247798B1 (en) * 2020-11-19 2025-08-27 Novartis AG Synthesis of prostate specific membrane antigen (psma) ligands
MX2021005089A (es) * 2021-04-30 2022-11-01 Instituto Nac De Investigaciones Nucleares Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos.
US20240299596A1 (en) * 2021-06-17 2024-09-12 Mayo Foundation For Medical Education And Research Methods and materials for combining biologics with multiple chelators
KR20230050552A (ko) * 2021-10-07 2023-04-17 (주)퓨쳐켐 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
AU2023413150A1 (en) * 2022-12-21 2025-06-26 Mayo Foundation For Medical Education And Research Methods and materials for combining biologics with multiple chelators
CN121604981A (zh) 2023-07-21 2026-03-03 诺华公司 靶向psma的放射性配体治疗方案

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082338A1 (en) 2011-11-30 2013-06-06 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof
JP2014524419A (ja) 2011-08-05 2014-09-22 モレキュラー インサイト ファーマシューティカルズ 放射標識された前立腺特異的膜抗原阻害剤
WO2015055318A1 (en) 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015171792A1 (en) 2014-05-06 2015-11-12 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
WO2016030329A1 (en) 2014-08-24 2016-03-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
WO2017116994A1 (en) 2015-12-31 2017-07-06 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700234T3 (es) * 2007-06-26 2019-02-14 Univ Johns Hopkins Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
US9422234B2 (en) 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
JP2012511024A (ja) 2008-12-05 2012-05-17 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 癌の治療及び撮像用のｃａ−ｉｘ特異性放射性医薬品
US9056841B2 (en) 2009-03-19 2015-06-16 The Johns Hopkins University PSMA-targeting compounds and uses thereof
EP3939972A1 (en) * 2013-01-14 2022-01-19 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3212610B1 (en) * 2014-10-30 2020-10-28 Katholieke Universiteit Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
US11520472B2 (en) * 2015-09-24 2022-12-06 Mitutoyo Corporation Inspection program editing environment including integrated alignment program planning and editing features

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524419A (ja) 2011-08-05 2014-09-22 モレキュラー インサイト ファーマシューティカルズ 放射標識された前立腺特異的膜抗原阻害剤
WO2013082338A1 (en) 2011-11-30 2013-06-06 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof
WO2015055318A1 (en) 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015171792A1 (en) 2014-05-06 2015-11-12 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
WO2016030329A1 (en) 2014-08-24 2016-03-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
WO2017116994A1 (en) 2015-12-31 2017-07-06 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Banerjee, Sangeeta R.; et al，Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)，Journal of Medicinal Chemistry ，2008年，51(15),，4504-4517
Banerjee, Sangeeta Ray; et al，Synthesis and Evaluation of GdIII-Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen，Angewandte Chemie, International Edition，2015年，54(37),，10778-10782
Benesova, Martina; Bauder-Wuest, Ulrike; Schaefer, Martin; Klika, Karel D.; Mier, Walter; Haberkorn, Uwe; Kopka, Klaus; Eder, Matthias，Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors，Journal of Medicinal Chemistry，2016年，59(5),，1761-1775
Cleeren, Frederik; Lecina, Joan; Billaud, Emilie M. F.; Ahamed, Muneer; Verbruggen, Alfons; Bormans, Guy M.，New Chelators for Low Temperature Al18F-Labeling of Biomolecules，Bioconjugate Chemistry，2016年，27(3),，790-798
Eder, Matthias; Schaefer, Martin; Bauder-Wuest, Ulrike; Hull, William-Edmund; Waengler, Carmen; Mier, Walter; Haberkorn, Uwe; Eisenhut, Michael，68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging，Bioconjugate Chemistry，2012年，23(4),，688-697
Schaefer, Martin; Bauder-Wuest, Ulrike; Leotta, Karin; Zoller, Frederic; Mier, Walter; Haberkorn, Uwe; Eisenhut, Michael; Eder, Matthias，A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer，EJNMMI Research，2012年，2(1),，23
Shallal, Hassan M.; Minn, Il; Banerjee, Sangeeta R.; Lisok, Ala; Mease, Ronnie C.; Pomper, Martin G.，Heterobivalent Agents Targeting PSMA and Integrin-αvβ3，Bioconjugate Chemistry，2014年，25(2),，393-405

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020522506A (ja) * 2017-05-30 2020-07-30 ザ・ジョンズ・ホプキンス・ユニバーシティ 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2023159182A (ja) * 2017-05-30 2023-10-31 ザ・ジョンズ・ホプキンス・ユニバーシティ 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Also Published As

Publication number Publication date
RS62274B1 (sr) 2021-09-30
BR112018069507A2 (pt) 2019-01-29
PT3925952T (pt) 2023-12-13
EP3433238B1 (en) 2021-06-16
US20250195700A1 (en) 2025-06-19
PH12018502048A1 (en) 2019-07-01
JP2022116028A (ja) 2022-08-09
US11458213B2 (en) 2022-10-04
JP2024050608A (ja) 2024-04-10
PL3925952T3 (pl) 2024-04-22
MX2018011519A (es) 2019-01-28
SI3433238T1 (sl) 2021-11-30
CN109311827A (zh) 2019-02-05
SA518400103B1 (ar) 2022-03-20
ZA201806389B (en) 2024-01-31
LT3433238T (lt) 2021-09-27
CN114716387B (zh) 2025-04-01
ES2877572T3 (es) 2021-11-17
DK3925952T3 (da) 2024-02-05
AU2017238181A1 (en) 2018-10-18
EP3433238A1 (en) 2019-01-30
EP4385981A1 (en) 2024-06-19
LT3925952T (lt) 2024-01-25
NZ746701A (en) 2024-12-20
NZ786380A (en) 2025-05-02
KR20220063298A (ko) 2022-05-17
MX384823B (es) 2025-03-14
SI3925952T1 (sl) 2024-03-29
TR201813644T1 (tr) 2018-11-21
US20230015736A1 (en) 2023-01-19
DK3433238T3 (da) 2021-09-06
PL3433238T3 (pl) 2021-12-13
EP3925952A1 (en) 2021-12-22
EP3925952B1 (en) 2023-11-29
HRP20240215T1 (hr) 2024-04-26
HUE055607T2 (hu) 2021-12-28
CN109311827B (zh) 2022-04-12
US20200155713A1 (en) 2020-05-21
RU2749399C2 (ru) 2021-06-09
HRP20211386T1 (hr) 2021-12-10
JP2019519467A (ja) 2019-07-11
CN120172884A (zh) 2025-06-20
RU2018133693A (ru) 2020-04-22
AU2017238181B2 (en) 2021-05-27
RS65188B1 (sr) 2024-03-29
CA3018709A1 (en) 2017-09-28
RU2018133693A3 (https=) 2020-04-22
PT3433238T (pt) 2021-07-28
HUE065327T2 (hu) 2024-05-28
FI3925952T3 (fi) 2024-02-13
CY1124487T1 (el) 2022-07-22
EP3433238A4 (en) 2019-09-11
WO2017165473A1 (en) 2017-09-28
JP2026021351A (ja) 2026-02-10
CL2018002683A1 (es) 2019-04-22
KR20250057132A (ko) 2025-04-28
KR102396307B1 (ko) 2022-05-09
CN114716387A (zh) 2022-07-08
KR20180134918A (ko) 2018-12-19
RU2021115958A (ru) 2021-07-12
KR20230147751A (ko) 2023-10-23
ES2972148T3 (es) 2024-06-11

Similar Documents

Publication Publication Date Title
JP7073270B2 (ja) 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP7821460B2 (ja) 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2025028897A (ja) Ｐｓｍａ標的化ガンイメージングまたは放射線療法中の健康組織保護のための２－ｐｍｐａのプロドラッグ
JP2020522506A5 (https=)
KR102531494B1 (ko) 탄산 탈수효소 ix를 표적으로 하는 핵 영상화 및 방사선치료 제제 및 이의 용도
US20210338846A1 (en) Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
US10434195B2 (en) Methylsulfonamide derivatives and uses related thereto
HK1259764B (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
US10912850B2 (en) 18F-FNDP for pet imaging of soluble epoxide hydrolase (sEH)
BR122025009780A2 (pt) Compostos, método para tratar uma ou mais células ou tumores que expressam psma in vitro ou ex vivo que utiliza os ditos compostos e uso dos mesmos para tratar tumores ou células que expressam psma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220511

R150 Certificate of patent or registration of utility model

Ref document number: 7073270

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250